# US 2016/0257680 A1 · Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257680 A1
- Document ID: US20160257680A1
- Status: Published application
- Kind: A1
- Application number: 15/031,301
- Filed: 2014-10-21
- Published: 2016-09-08
- Earliest claimed: 2013-10-22
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Yaofeng Cheng; Weiqi Chen; Brad D. Maxwell; Bach D. Tran; Jun Li
- Web page: https://patentgrep.com/patent/US20160257680A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- C07B 59/002: {Heterocyclic compounds}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein R* is an isotopically labeled hydroxypropyl moiety.

## Claims

### Claim 1

A compound, enantiomer, diastereomer, or salt thereof, of a compound of formula I:
wherein R* is an isotopically labeled hydroxypropyl moiety.

### Claim 2 (depends on 1)

The compound, enantiomer, diastereomer, or salt thereof, of claim 1, wherein the compound is a compound of formula Ia, Ib, Ic, Id, Ie, If or Ig:

### Claim 3 (depends on 1)

The compound, enantiomer, diastereomer, or salt thereof, of claim 1, wherein the compound is a compound of formula Ia:

### Claim 4 (depends on 1)

The compound, enantiomer, diastereomer, or salt thereof, of claim 1, wherein the compound is a compound of formula Ib:

### Claim 5 (depends on 1)

The compound, enantiomer, diastereomer, or salt thereof, of claim 1, wherein the compound is a compound of formula Ic:

### Claim 6 (depends on 1)

The compound, enantiomer, diastereomer, or salt thereof, of claim 1, wherein the compound is a compound of formula Id:

### Claim 7 (depends on 1)

The compound, enantiomer, diastereomer, or salt thereof, of claim 1, wherein the compound is a compound of formula Ie:

### Claim 8 (depends on 1)

A compound, enantiomer, diastereomer, or salt thereof, of claim 1, wherein the compound is a compound of formula If:

### Claim 9 (depends on 1)

A compound, enantiomer, diastereomer, or salt thereof, of claim 1, wherein the compound is a compound of formula Ig:

### Claim 10

A compound, enantiomer, diastereomer, or salt thereof, of a compound of formula II:

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10 further comprising at least one additional therapeutic agent.

### Claim 13 (depends on 1)

A method for treating, preventing, or slowing the progression of diabetes, atherosclerosis, hyperglycemia, obesity, dyslipidemia, hypertension, cognitive impairment, rheumatoid arthritis, osteoarthritis, glaucoma, Cushing's Disease and Metabolic Syndrome, which comprises administering to a mammalian patient in need of treatment a therapeutically effective amount of at least one compound, enantiomers, diastereomers, or salts thereof, of claim 1.

### Claim 14 (depends on 1)

A method for treating, preventing, or slowing the progression of diabetes, which comprises administering to a mammalian patient in need of treatment a therapeutically effective amount of at least one compound, enantiomers, diastereomers, or salts thereof, of claim 1.

### Claim 15 (depends on 1)

A method for treating, preventing, or slowing the progression of atherosclerosis or dyslipidemia, which comprises administering to a mammalian patient in need of treatment a therapeutically effective amount of at least one compound, enantiomers, diastereomers, or salts thereof, of claim 1.
